Current status and future directions of radioimmunotherapy (original) (raw)

• Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart URW, Kubista TP, Poon MA, Meyers WC, Mailliard JA, Twito DI, Morton RF, Veeder MH, Witzig TE, Cha S, Vidyarthi SC: Effective surgical adjuvant therapy for high-risk carcinoma. N Engl J Med 1991;324:709–715.
  Article PubMed CAS Google Scholar
• Laufman LR, Bukowski RM, Collier MA, Sullivan BA, McKinnis RA, Clendennin NJ, Guaspari A, Brenckman WD jr: A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1993;11:1888–1893.
  PubMed CAS Google Scholar
• Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A: Phase II study of fluorouracil and is modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol 1995;13:1303–1311.
  PubMed CAS Google Scholar
• Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rates. J Clin Oncol 1992;10:896–903.
  Google Scholar
• Moertel C, Fleming TR, MacDonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–358.
  Article PubMed CAS Google Scholar
• International Multicenter Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939–944.
  Article Google Scholar
• Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raah R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J, German Cancer Aid 17-1A Study Group: Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 1994;343:1177–1183.
  Article PubMed Google Scholar
• Weinberg MJ, Rauth AM: 5-Fluorouracil infusions and fractionated doses of radiation: studies with murine squamous cell carcinoma. Int J Radiat Oncol Biol Phys 1987;13:1691–1699.
  PubMed CAS Google Scholar
• Byfield JE, Chan PYM, Seagren SL: Radiosensitization by 5-FU: molecular origins and clinical scheduling implication. Proc Amm Asoc Cancer Res 1977;18:74.
  Google Scholar
• Oettgen HF, Old LJ: The history cancer immunotherapy, in DeVita VT jr, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer. Philadelphia, Lippincott, 1991, pp 87–119.
  Google Scholar
• Caron PC, Co MS, Bull MK, et al: Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 1992;52:6761–6767.
  PubMed CAS Google Scholar
• Trauth BC, Klas C, Peters Am, et al: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301–305.
  Article PubMed CAS Google Scholar
• Herlyn D, Wettendorff M, Schmoll E, et al: Anti-idiotype immunization of cancer patients: Modulation of the immune response. Proc Natl Acad Sci USA 1987;84:8055–8059.
  Article PubMed CAS Google Scholar
• Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–497.
  Article PubMed Google Scholar
• Wilder RB, DeNardo GL, DeNardo SJ: Radioimmunotherapy: Recent results and future directions. J Clin Oncol 1996;14:1383–1400.
  PubMed CAS Google Scholar
• Buchsbaum DJ, Wessels BW: Introduction: Radiolabeled antibody tumor dosimetry. Med Phys 1993;20:499–501.
  Article PubMed CAS Google Scholar
• Langmuir VK, McGann JK, Buchegger F, et al: The effect of antigen concentration, antibody valency and size, and tumor architecture on antibody binding in multicell spheroids. Int J Rad Appl Instrum (B) 1991;18:753–764.
  CAS Google Scholar
• Welt S, Divgi CR, Real FX, Yeh SD, Garin Chesa P, Finstad CL, Sakamoto J, Cohen A, Sigurdson ER, Kemeny N, Carswell EA, Oettgen HF, Old LL: Quantitative analysis of antibody licalization in human metastatic colon cancer: a phase I study with monoclonal antibody A33. J Clin Oncol 1990;8:1894–1906.
  PubMed CAS Google Scholar
• Leichner PK, Koral KF, Jaszczak RJ, et al: An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy. Med Phys 1993;20:569–577.
  Article PubMed CAS Google Scholar
• Fowler JF. Intercomparisons of new and old schedules in fractionated radiotherapy. Sem Radiat Oncol 1992;2:67–72.
  Article Google Scholar
• Buchsbaum DJ, Ten Haken RK, Heidorn DB, Lawrence TS, Glatfelter AA, Terry VH, Guilbault DM, Steplewski Z, Lichter AS: A comparison of131I-labeled monoclonal antibody 17-1A treatment to external beam radiation on the growth of LS174T human colon cancer. Int J Radiat Oncol Biol Phys 1990;18:1033–1041.
  PubMed CAS Google Scholar
• Buras RR, Wong JYC, Kuhn JA: Comparison of radioimmunotherapy and external beam radiation in colon cancer. Int J Radiat Oncol Biol Phys 1991;16:12–16.
  Google Scholar
• Vessella RL, Palme DF, Berkopec JM, Elson MK, Truillo G, Wessels BW, Lange PH: A comparison of escalating single and multiple fraction low dose rate radioimmunotherapy with monoclonal antibody A6H I-131 conjugates to high dose rate external beam therapy on human renal cell carcinoma xenografts. J Nucl Med 1988;29:875.
  Google Scholar
• Winograd B, Boven E, Lobezzo MW, Pinedo HM: Human tumor xenografts in the nude mouse and their value as test models in anti-cancer drug development. In Vivo 1987;1:1–14.
  PubMed CAS Google Scholar
• Schwachhofer JHM, Hoogenhout J, Kal B, Koedam J, Van Wezel HPN: Radiosensitivity of different human tumor lines grown as xenografts determined from growth delay and survival data. In Vivo 1990;4:253–258.
  Google Scholar
• Buchsbaum DJ: Experimental radioimmunotherapy: Methods to increase therapeutic efficacy relevant to the study of human cancer. Antib Immunoconj Radiopharm 1991;4:693–701.
  Google Scholar
• Buchsbaum DJ, Lawrence TS: Tumor therapy with radiolabeled monoclonal antibodies. Antib Immunoconj Radiopharm 1991;4:245–272.
  Google Scholar
• Yokoyama K, Reynolds JC, Paik CH, Sood VK, Maloney PJ, Larson SM, Reba RC: Immunoreactivity affects the biodistribution and tumor targeting of radiolabeled anti-P97 Fab fragment. J Nucl Med 1990;31:202–210.
  PubMed CAS Google Scholar
• Schlom J, Eggensperger D, Colcher D, Molinolo A, Houchens D, Miller LS, Hinkle G, Siler K: Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992;52:1067–1072.
  PubMed CAS Google Scholar
• Blumenthal RD, Sharkey RM, Kashi R, Natale AM, Goldenberg DM: Influence of animal host and tumor implantation on radioantibody uptake in the GW-39 human colonic cancer xenograft. Int J Cancer 1989;44:1041–1047.
  Article PubMed CAS Google Scholar
• Shockley TR, Lin K, Sung C, Nagy JA, Tompkins RG, Dedrick RL, Dvorak HF, Yarmush ML: A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: Effects of antibody immunological properties and tumor antigen expression levels. Cancer Res 1992;52:357–366.
  PubMed CAS Google Scholar
• Rowlinson G, Balkwill F, Snook D, Hooker G, Epenetos AA: Enhancement by g-interferon of in vivo tumor radiolocalization by a monoclonal antibody against HLA-DR antigen. Cancer Res 1986;46:6413–6417.
  PubMed CAS Google Scholar
• Rosenblum MG, Lamki LM, Murray JL, Carlo DJ, Gutterman JU: Interferon-induced changes in pharmacokinetics and tumor uptake of 111In-labeled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst 1988;80:160–165.
  Article PubMed CAS Google Scholar
• Goldenberg DM, Blumenthal RD, Sharkey RM: Biological and clinical perspectives of cancer imaging and therapy with radiolabeled antibodies. Sem Cancer Biol 1990;1:217–225.
  CAS Google Scholar
• Jain RK. Haemodynamic and transport barriers to treat solid tumours. Int J Radiat Biol 1991;60:85–100.
  PubMed CAS Google Scholar
• Ongl GL, Mattes MJ: Penetration and binding of antibodies in experimental human solid tumors grown in mice. Cancer Res 1989;49:4264–4273.
  Google Scholar
• Barendswaard EC, Scott AM, Divgi CR, Williams C jr, Coplan K, Riedel E, Yao TJ, Gansow OA, Finn RD, Larson SM, Old LJ, Welt S: Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice. Int J Oncol 1998;12:45–53.
  PubMed CAS Google Scholar
• Goldenberg DM, Gaffar SA, Bennett SJ, Beach JL: Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res 1981;41:4354–4360.
  PubMed CAS Google Scholar
• Sharkey RM, Pykett MJ, Siegel JA, Alger EA, Primus FJ, Goldenberg DM: Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131-I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res 1987;47:5672–5677.
  PubMed CAS Google Scholar
• Esteban JM, Schlom J, Mornex F, Colcher D: Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: Histological and autoradiographic study of effects on tumors and normal organs. Eur J Cancer Clin Oncol 1987;23:643–655.
  Article PubMed CAS Google Scholar
• Zalcberg JR, Thompson CH, Lichtenstein M, McKenzie IFC: Tumor immunotherapy in the mouse with the use of131I-labeled monoclonal antibodies. J Natl Cancer Inst 1984;72:697–704.
  PubMed CAS Google Scholar
• Schlom J, Molinolo A, Simpson JF, Siler K, Roselli M, Hinkle G, Houchens DP, Colcher D: Advantage of dose frationation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 1990;82:763–771.
  Article PubMed CAS Google Scholar
• Blumenthal RD, Sharkey RM, Haywood L, Natale AM, Wong GY, Siegel JA, Kennel SJ, Goldenberg DM: Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with131I-labeled monoclonal antibodies. Cancer Res 1992;52:6036–6044.
  PubMed CAS Google Scholar
• Sharkey RM, Weadock KS, Natale A, Haywood L, Aninipot R, Blumenthal RD, Goldenberg DM: Successful radioimmunotherapy for lung metastasis of human colonic cancer in nude mice. J Natl Cancer Inst 1991;83:627–632.
  Article PubMed CAS Google Scholar
• Blumenthal RD, Shareky RM, Natale AM, Kashi R, Wong GY, Goldenberg DM: Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res 1994;54:142–152.
  PubMed CAS Google Scholar
• Buchegger F, Pelegrin A, Delaloye B, Bischof-Delaloye A, Mach JP: Iodine-131-labeled Mab F(ab)2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med 1990;31:1035–1044.
  PubMed CAS Google Scholar
• Blumenthal RD, Sharkey RM, Kashi R, Goldenberg DM: Comparison of therapeutic efficacy and host toxicity of two different131I-labeled antibodies and their fragments in the GW-39 colonic cancer xenograft model. Int J Cancer 1989;44:292–300.
  Article PubMed CAS Google Scholar
• Morton BA, Beatty BG, Mison A, Wanck PM, Beatty JD: Role of bone marrow transplantation in yttrium-90 antibody therapy of colon cancer xenografts in nude mice. Cancer Res 1990:50 (suppl): 1008s-1010s.
  PubMed CAS Google Scholar
• Gallicchio VS, Hulette BC, Messino MJ, Gass C, Bieschke MW, Doukas MA: Effect of various interleukin (IL-1, IL-2, and IL-3) on the in vitro radioprotection of bone marrow progenitors (CFU-GM and CFU-MEG). J Biol Response Mod 1989;8:479–487.
  PubMed CAS Google Scholar
• Pedley RB, Begent RHJ, Boden JA, Boden R, Adam T, Bagshawe KD: The effect of radiosensitizers on radioimmunotherapy, using131I-labeled anti-CEA antibodies in a human colonic xenograft model. Int J Cancer 1991;47:597–602.
  Article PubMed CAS Google Scholar
• Koizumi K, DeNardo GL, DeNardo SJ, et al: Multicompartimental analysis of the kinetics of radioiodinated monoclonal antibody in patients with cancer. J Nucl Med 1986;27:1243–1254.
  PubMed CAS Google Scholar
• Goldenberg DM (ed): Cancer therapy with radiolabeled antibodies. Boca Raton, CRC Press, 1995.
  Google Scholar
• Colcher D, Esteban JM, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G. et al: Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Res 1987;47:1185–1189.
  PubMed CAS Google Scholar
• Delaloye AB, Delaloye B, Buchegger F, Vogel CA, Gillet M, Mach JP, Smith A, Schubiger PA: Comparison of copper-67-and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors. J Nucl Med 1997;38:847–853.
  PubMed CAS Google Scholar
• Begent RH, Ledermann JA, Green JA, et al: Antibody distribution and dosimetry in patients receiving radiolabeled antibody therapy for colorectal cancer. Br J Cancer 1989;60:406–412.
  PubMed CAS Google Scholar
• Meredith RF, Bueschen AJ, Khazaeli MB, et al: Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med 1992;33:23–29.
  PubMed CAS Google Scholar
• Murray JL, Macey DJ, Kasi LP, et al: Phase II radioimmunotherapy trial with131I-CC49 in colorectal cancer. Cancer 1994;73:1057–1066.
  Article PubMed CAS Google Scholar
• Welt S, Divgi CR, Kemendy N, Finn RD, Scott AM, Graham M, St. Germain J, Carswell Richards E, Larson SM, Oettgen HF, Old LJ: Phase I/II study of iodine 131-labeled monoclonal antibody A 33 in patients with advanced colon cancer. J Clin Oncol 1994;12:1561–1571.
  PubMed CAS Google Scholar
• Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, St. Germain J, Richards EC, Larson SM, Old LJ. Phase I/II study of iodine 125-labeled monoclonal antibody A33 patients with advanced colon cancer. J Clin Oncol 1996;14:1787–1797.
  PubMed CAS Google Scholar
• Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, Zhang CH, Swayne LC, Vardi Y, Siegel JA, Goldenberg DM: Phase I/II clinical radioimmunotherapy with iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 1997;38:858–870.
  PubMed CAS Google Scholar
• Sgouros G: Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle (ed). J Nucl Med 1995;36:1910–1912.
  PubMed CAS Google Scholar
• Greiner JW, Ullmann CD, Nieroda C, et al: Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon. Cancer Res 1993;53:600–608.
  PubMed CAS Google Scholar
• LeBerthon B, Khawli LA, Alauddin M, et al: Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res 1991;51:2694–2698.
  PubMed CAS Google Scholar
• Msirikale JS, Klein JL, Schroeder J, et al: Radiation enhancement of radiolabeled antibody desposition in tumors. Int J Radiat Oncol Biol Phys 1987;13:1839–1844.
  PubMed CAS Google Scholar
• Langmuir VK, Mendonca HL: The combined use of131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo (published erratum in Radiat Res 1990). Radiat Rese 1992;132:351–358.
  Article CAS Google Scholar
• Wilder RB, Langmuir VK, Mendonca HL, et al: Local hyperthermia and SR 4233 enhanced the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts. Cancer Res 1993;53:3022–3027.
  PubMed CAS Google Scholar
• Tschmelitsch J, Barendswaard E, Williams C jr, Yao TJ, Cohen AM, Old LJ, Welt S: Enhanced antitumor activity of combined radioimmunotherapy (131-I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res 1997;57:2181–2186.
  PubMed CAS Google Scholar